With all of the problems and challenges facing Canada’s healthcare today, one of the topics garnering much attention is that of pharmacare, or more precisely drug coverage and reimbursement. And for good reason. Among the OECD countries Canada has one of the worst bundles of public drug coverage and reimbursement: long-delayed access (if any access at all) to new and more effective drugs; next to no coverage for biologics, orphan drugs and personalized medicines; huge out-of-pocket payments; a large privately uninsured population also not eligible for public coverage.
In the last decade, at least four reports have been released but no solution has been reached. In this document, The Cameron Institute’s patient expert, Professor Emeritus at the University of Alberta, and a former senior civil servant in Health Canada, provides his opinion about the Canadian Pharmacists Association’s (CPhA) commissioned report regarding costing of various national/pan-Canadian drug options.